In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19

Set Alert for COVID-19

The Case For Covaxin: Ocugen CEO Shankar Musunuri

A potential decline in mRNA vaccine protection against the Delta variant is raising questions about the need for booster shots in the US. Ocugen Inc. and partner Bharat Biotech hope the changing dynamic of COVID-19 in the US will induce the FDA to reconsider additional clinical trial requirements for Covaxin, an inactivated whole virus vaccine authorized for emergency use in 16 countries. 

Coronavirus COVID-19 Leadership

Royal Philips’ IGT Goes For The Structural Heart

Royal Philips’ image-guided therapy business has rebounded, as expected, after the COVID-19 dip, and is now targeting expansion in a number of areas, as business leader Bert van Meurs explains. 

Market Access Medical Device

The Medicines Patent Pool Plots A Post-Pandemic Future: Interview With Director Charles Gore

As the global access debate adapts to the stark inequities exposed by the COVID-19 pandemic, the UN-backed Medicines Patent Pool is emerging as a key player on issues ranging from vaccine tech transfer to making more drugs affordable against the spread of non-communicable diseases like cancer to middle- and low-income countries.

Intellectual Property Market Access

Finding Solutions For COVID Vaccine Distribution In Africa’s ‘Last Mile’

More COVID-19 vaccines are beginning to flow into Africa, as coordination between partner organizations and African governmental agencies improves. However, gaps remain in cold chain storage, information flow on the ground is lagging and vaccine hesitancy persists. Also, pandemic-related economic depression in some African countries is jeopardizing procurement and access to vaccines. 

Coronavirus COVID-19 Middle East and Africa

The Big Health Care Conundrum: How To Sustainably Unlock The Value Of Diagnostics

With COVID-19 a residual but still very real issue globally, Novo Holdings asked the big diagnostics question at a recent high-level roundtable: How can stakeholders capitalize on this moment of acute public awareness of diagnostics to improve adoption of tests and screening in the long term? The CEOs of Roche Diagnostics, GE Healthcare, Labcorp and Synlab, among others, gave their thoughts on how the system must change.

Market Access In Vitro Diagnostics

Pandemic ‘Dividend’ Must Not Be Squandered

Maintaining the positive changes that health care delivery underwent at the height of COVID-19 has been the talk of the health care industries, but will commercial organizations retain their enthusiasm once the pressures of the pandemic abate?

Leadership In Vitro Diagnostics

Civil Society Groups Use COVID To Build Stronger Narrative For Equal Access

The divide between developed and developing countries for access to health care innovations has been spotlighted by the ongoing COVID-19 pandemic. Civil society groups pile on the pressure.

Coronavirus COVID-19 Market Access

The Missing Link: COVID-19 Antibody Tests Need Buy-In From FDA

Concern looms in many countries as cases of COVID-19 continue to rise due to the delta variant. Vaccines are having a positive effect, but what is the outlook for those still vulnerable to the virus after inoculation? Not everyone will respond to vaccinations in the same way.

Market Access Coronavirus COVID-19

All Change For UK Health Care: Global Medtech Keeps A Close Watch

Shaped by Brexit, driven by COVID, squeezed by budgets and being engineered for the future, it seems that almost every element within UK health delivery and market access is undergoing change. How should the medtech industry prepare, and will there be implications beyond the UK?

United Kingdom Market Intelligence

The Indemnity Calculus For Covid-19 Vaccines, India’s Path Ahead

Legal experts discuss the intricacies around pharma’s demand for indemnity, a key sticking point for supplies of COVID-19 vaccines from Pfizer and Moderna, and the path forward for countries like India.

India Commercial

Pacifying A Pandemic With Numbers

Powered by prominent global health philanthropies and the UK’s world-class collaborative capabilities in disease surveillance, the new International COVID-19 Data Alliance (ICODA) is gearing up to address a crucial – and yet unanswered – policy question for public health:  can sharing data curated from a diversity of sources provide the hard evidence needed to improve patient outcomes against the virus – not just for today’s pandemic, but for future ones as well? Much will depend on a robust response from big pharma.

Coronavirus COVID-19 Clinical Trials

Making The Most Of A Renaissance Moment In Health Care

The rise of digital alongside long-established physical methods of care delivery should not give rise to notions of an "either/or" choice, but should rather be seen as an “and,” said Accenture’s Andrew Meade in conversation with In Vivo.

Business Strategies Clinical Trials

How COVID Boosted Medtech In The Eyes Of The World

Reaching deep and being resourceful were the in-demand attributes that medtech industry leaders brought to bear when the COVID-19 pandemic stretched health care providers almost to breaking point.

Leadership Medical Device

Health Care Provider C-Suite Energized By Pandemic Crisis

Royal Philips anticipated a degree of negative sentiment from health system managers about the outlook for innovation and progress in health care delivery when it polled the provider C-suite for its 2021 Future Health Index report. It was surprised by the actual outcome.

Leadership Telehealth

Setting Ego Aside To Better Human Health

Kate Broderick, SVP of research and development at INOVIO and one of In Vivo’s 2021 rising leaders, is hopeful that greater collaboration will be the lasting effect of COVID-19.

C-Suite Speaks Commercial

Market Access After COVID-19: Sector Goodwill Or Hard Crackdown?

The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.

Commercial Companies
See All
UsernamePublicRestriction

Register